Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.

$2.1B

Market Cap • 5/12/2025

2022

(3 years)

Founded

2022

(3 years ago)

IPO

NYSE

Listing Exchange

Flag of US

New Haven

Headquarters • Connecticut